GRK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2566502	0.59	7/20
SCHEMBL2566259	0.58	7/20
SCHEMBL2570619	0.58	7/20
SCHEMBL2566979	0.55	7/20
SCHEMBL2567097	0.68	6/20
SCHEMBL2570138	0.68	6/20
SCHEMBL2568170	0.66	6/20
SCHEMBL2566455	0.61	6/20
SCHEMBL2566609	0.60	6/20
SCHEMBL2567360	0.59	6/20
SCHEMBL2569328	0.58	6/20
SCHEMBL2563308	0.57	6/20
SCHEMBL2566190	0.57	6/20
SCHEMBL2570860	0.56	6/20
SCHEMBL2566283	0.56	6/20
SCHEMBL2566664	0.56	6/20
SCHEMBL2568374	0.55	6/20
SCHEMBL2566174	0.51	6/20
SCHEMBL4506582	0.50	6/20
SCHEMBL2565824	0.49	6/20

Clinical trials — most relevant to GRK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)	PHASE2	ACTIVE_NOT_RECRUITING
Dose Ranging Study of Carbidopa-levodopa	PHASE2	COMPLETED
Carbidopa-levodopa in Neovascular AMD	PHASE2	COMPLETED
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration	PHASE2	WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle	PHASE2	NOT_YET_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.	PHASE2	COMPLETED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Genetic Predictors of Lithium Response in Bipolar Disorder	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Acamprosate: Genes Associated With Response	nan	COMPLETED
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors	nan	WITHDRAWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
Identification of Cellular Biomarkers of Rare Eye Diseases in Adults	nan	NOT_YET_RECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour	nan	UNKNOWN
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Rod and Cone Mediated Function in Retinal Disease	nan	RECRUITING
Effect of Symbicort on GR Localisation in Asthma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRK1 binder may also engage these)

Protein	Name	Similarity
Q9WVL4	—	1.000	Q9WVL4 →
Q63651	—	0.999	Q63651 →
P28327	—	0.997	P28327 →
Q8WP15	—	0.994	Q8WP15 →
Q9Z2G7	—	0.989	Q9Z2G7 →
Q8WMV0	—	0.986	Q8WMV0 →
GRK7	Rhodopsin kinase GRK7	0.984	landscape →
B6CZ17	—	0.980	B6CZ17 →
B6CZ18	—	0.978	B6CZ18 →
P62205	—	0.978	P62205 →
PRKCA	Protein kinase C alpha type	0.977	landscape →
P32866	—	0.975	P32866 →
Q1XHL7	—	0.975	Q1XHL7 →
Q622Z7	—	0.974	Q622Z7 →
PRKCB	Protein kinase C beta type	0.974	landscape →
O54992	—	0.974	O54992 →
Q9Z265	—	0.973	Q9Z265 →
Q8BPM2	—	0.973	Q8BPM2 →
O54785	—	0.973	O54785 →
Q49HM9	—	0.972	Q49HM9 →
P05696	—	0.972	P05696 →
Q28GW8	—	0.971	Q28GW8 →
P53666	—	0.971	P53666 →
P10102	—	0.971	P10102 →
A8KBH6	—	0.971	A8KBH6 →
Q09537	—	0.971	Q09537 →
P70032	—	0.971	P70032 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.971	landscape →
LIMK2	LIM domain kinase 2	0.971	landscape →
CHEK2	Serine/threonine-protein kinase Chk2	0.971	landscape →